amlodipine has been researched along with Chronic Illness in 58 studies
Amlodipine: A long-acting dihydropyridine calcium channel blocker. It is effective in the treatment of ANGINA PECTORIS and HYPERTENSION.
amlodipine : A fully substituted dialkyl 1,4-dihydropyridine-3,5-dicarboxylate derivative, which is used for the treatment of hypertension, chronic stable angina and confirmed or suspected vasospastic angina.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study was designed to test the hypothesis of whether amlodipine reduces the risk for death in patients with heart failure due to a nonischemic cardiomyopathy." | 9.17 | Effect of amlodipine on the survival of patients with severe chronic heart failure due to a nonischemic cardiomyopathy: results of the PRAISE-2 study (prospective randomized amlodipine survival evaluation 2). ( Anderson, SA; Carson, P; DeMets, DL; Elkayam, U; Konstam, MA; Moe, G; O'Connor, C; Packer, M; Rouleau, JL; Schocken, D, 2013) |
| " In this study, we conducted an open-label and randomized trial to compare the effects of benidipine with those of amlodipine on blood pressure (BP), albuminuria and aldosterone concentration in hypertensive patients with mild-to-moderate stage chronic kidney disease (CKD)." | 9.15 | Benidipine reduces albuminuria and plasma aldosterone in mild-to-moderate stage chronic kidney disease with albuminuria. ( Abe, M; Fujita, T; Maruyama, N; Maruyama, T; Matsumoto, K; Matsumoto, S; Okada, K; Soma, M, 2011) |
| "This multicentre, double-blind, trial in subjects with severe hypertension compared the efficacy and tolerability of two parallel drug regimens: A/B (amlodipine/benazepril: 5/20 or 10/40 mg daily, if necessary) with A (amlodipine: 5 or 10 mg daily, if necessary)." | 9.14 | Comparative efficacy and safety of amlodipine/benazepril combination therapy and amlodipine monotherapy in severe hypertension. ( Hall, D; Hilkert, RJ; Izzo, JL; Purkayastha, D, 2010) |
| "The present study was conducted to compare the renal and vascular protective effects of telmisartan and amlodipine in untreated hypertensive chronic kidney disease (CKD) patients with moderate renal insufficiency." | 9.13 | Comparison of renal and vascular protective effects between telmisartan and amlodipine in hypertensive patients with chronic kidney disease with mild renal insufficiency. ( Inoue, T; Kawagoe, Y; Koide, H; Nakamura, T; Node, K; Suzuki, T; Ueda, Y, 2008) |
| " The present study compared the chronic effects of efonidipine and amlodipine on proteinuria in patients with chronic glomerulonephritis." | 9.12 | Efonidipine reduces proteinuria and plasma aldosterone in patients with chronic glomerulonephritis. ( Akashiba, A; Ishimitsu, T; Kameda, T; Matsuoka, H; Minami, J; Numabe, A; Ohta, S; Ono, H; Takahashi, T; Yoshii, M, 2007) |
| "The results of this study show that once daily amlodipine offers comparable antianginal and antiischemic efficacy as twice daily sustained release nifedipine in the monotreatment of chronic stable angina pectoris." | 9.09 | [Amlodipine versus nifedipine retard. A randomized double-blind comparative study on long-term efficacy and safety of amlodipine and nifedipine retard in the monotherapy of chronic stable angina pectoris]. ( Kupper, W; Sauerbrey-Wullkopf, N, 2001) |
| "Amlodipine did not increase cardiovascular morbidity or mortality in patients with severe heart failure." | 9.08 | Effect of amlodipine on morbidity and mortality in severe chronic heart failure. Prospective Randomized Amlodipine Survival Evaluation Study Group. ( Belkin, RN; Carson, PE; Cropp, AB; DeMets, DL; Frid, D; Ghali, JK; Miller, AB; Neuberg, GW; O'Connor, CM; Packer, M; Pressler, ML; Wertheimer, JH, 1996) |
| "To assess the effect of short-term amlodipine therapy on baseline measures of sympathetic activity and baroreflex function in patients with chronic stable congestive heart failure (CHF)." | 9.08 | Effect of amlodipine on norepinephrine kinetics and baroreflex function in patients with congestive heart failure. ( Goldsmith, SR, 1997) |
| "This study evaluated the safety, antianginal and antiischemic effects of amlodipine, a dihydropyridine calcium antagonist, in patients with chronic stable angina pectoris." | 9.06 | Clinical safety and efficacy of once-a-day amlodipine for chronic stable angina pectoris. ( Glasser, SP; West, TW, 1988) |
| "Background Amlodipine is used for the treatment of hypertension, but reports on its use in early pregnancy are limited." | 7.91 | Safety of Amlodipine in Early Pregnancy. ( Arata, N; Ito, S; Kamiya, CA; Mikami, M; Mito, A; Miyasato-Isoda, M; Murashima, A; Suzuki, T; Wada, Y; Waguri, M; Watanabe, O; Yakuwa, N; Yoshimatsu, J, 2019) |
| "Treatment with candesartan cilexetil reduced the level of ADMA in hypertensive patients in the chronic stage of cerebral infarction." | 7.83 | Effects of Candesartan Cilexetil Compared with Amlodipine on Serum Asymmetric Dimethylarginine Levels in the Chronic Stage of Cerebral Infarction: A Preliminary Study. ( Katayama, Y; Nishiyama, Y; Nomura, K; Sunami, E, 2016) |
| " Male Wistar rats with ligation-induced myocardial infarction were assigned to placebo or treatment with mibefradil (10 mg/kg/day), verapamil (8 mg/kg/day), or amlodipine (4 mg/kg/day) by oral gavage starting 7 days before the induction of myocardial infarction." | 7.70 | Differential effects of mibefradil, verapamil, and amlodipine on myocardial function and intracellular Ca(2+) handling in rats with chronic myocardial infarction. ( Meissner, A; Min, JY; Sandmann, S; Simon, R; Unger, T, 1999) |
| "The authors report the results of therapy with amlodipine in 20 patients with mild or moderate hypertension (diastolic pressure between 95 and 115 mmHg)." | 7.68 | [Experience with amlodipine (Norvasc) in the management of arterial hypertension]. ( Domínguez, B; Rodríguez, N, 1993) |
| "This multicenter, randomized, double-blind, parallel group, placebo lead-in, placebo-controlled study compared the antianginal and anti-ischemic effects of once-daily bedtime dosing of controlled-onset extended-release (COER-24) verapamil to a once-daily morning dosing of amlodipine +/- atenolol in patients with chronic stable angina." | 6.69 | Comparison of controlled-onset, extended-release verapamil with amlodipine and amlodipine plus atenolol on exercise performance and ambulatory ischemia in patients with chronic stable angina pectoris. ( Deedwania, PC; Fakouhi, TD; Frishman, WH; Glasser, S; Johnson, M; Stone, P, 1999) |
| "Mibefradil-treated patients showed greater decreases in heart rate and the rate-pressure product at each stage of the ETT than patients treated with amlodipine or diltiazem SR." | 6.68 | Mibefradil in the treatment of chronic stable angina pectoris: comparative studies with other calcium antagonists. ( Davies, GJ; Kobrin, I; Tzivoni, D, 1997) |
| "Mibefradil is a recently developed calcium antagonist with a unique chemical structure, pharmacologic profile, and mode of action." | 6.40 | Mibefradil, a T-type channel-selective calcium antagonist: clinical trials in chronic stable angina pectoris. ( Massie, BM, 1998) |
| "Hypertension is a chronic condition that requires lifelong therapeutic management." | 5.62 | Long-acting tunable release of amlodipine loaded PEG-PCL micelles for tailored treatment of chronic hypertension. ( Chua, CYX; Di Trani, N; Grattoni, A; Liu, HC; Liu, X; Qi, R; Viswanath, DI, 2021) |
| " In 11 patients concomitantly treated with cyclosporine the dosage and the trough-level of this agent were stable throughout the trial." | 5.31 | Antihypertensive efficacy of amlodipine in children with chronic kidney diseases. ( Bianchetti, MG; Bianda, ND; Casaulta Aebischer, C; Franscini, LM; Pfister, R; von Vigier, RO, 2001) |
| "This study was designed to test the hypothesis of whether amlodipine reduces the risk for death in patients with heart failure due to a nonischemic cardiomyopathy." | 5.17 | Effect of amlodipine on the survival of patients with severe chronic heart failure due to a nonischemic cardiomyopathy: results of the PRAISE-2 study (prospective randomized amlodipine survival evaluation 2). ( Anderson, SA; Carson, P; DeMets, DL; Elkayam, U; Konstam, MA; Moe, G; O'Connor, C; Packer, M; Rouleau, JL; Schocken, D, 2013) |
| " In this study, we conducted an open-label and randomized trial to compare the effects of benidipine with those of amlodipine on blood pressure (BP), albuminuria and aldosterone concentration in hypertensive patients with mild-to-moderate stage chronic kidney disease (CKD)." | 5.15 | Benidipine reduces albuminuria and plasma aldosterone in mild-to-moderate stage chronic kidney disease with albuminuria. ( Abe, M; Fujita, T; Maruyama, N; Maruyama, T; Matsumoto, K; Matsumoto, S; Okada, K; Soma, M, 2011) |
| "This multicentre, double-blind, trial in subjects with severe hypertension compared the efficacy and tolerability of two parallel drug regimens: A/B (amlodipine/benazepril: 5/20 or 10/40 mg daily, if necessary) with A (amlodipine: 5 or 10 mg daily, if necessary)." | 5.14 | Comparative efficacy and safety of amlodipine/benazepril combination therapy and amlodipine monotherapy in severe hypertension. ( Hall, D; Hilkert, RJ; Izzo, JL; Purkayastha, D, 2010) |
| "The present study was conducted to compare the renal and vascular protective effects of telmisartan and amlodipine in untreated hypertensive chronic kidney disease (CKD) patients with moderate renal insufficiency." | 5.13 | Comparison of renal and vascular protective effects between telmisartan and amlodipine in hypertensive patients with chronic kidney disease with mild renal insufficiency. ( Inoue, T; Kawagoe, Y; Koide, H; Nakamura, T; Node, K; Suzuki, T; Ueda, Y, 2008) |
| "To compare rates of coronary heart disease (CHD) and end-stage renal disease (ESRD) events; to determine whether glomerular filtration rate (GFR) independently predicts risk for CHD; and to report the efficacy of first-step treatment with a calcium-channel blocker (amlodipine) or an angiotensin-converting enzyme inhibitor (lisinopril), each compared with a diuretic (chlorthalidone), in modifying cardiovascular disease (CVD) outcomes in high-risk patients with hypertension stratified by GFR." | 5.12 | Cardiovascular outcomes in high-risk hypertensive patients stratified by baseline glomerular filtration rate. ( Barzilay, J; Batuman, V; Davis, BR; Eckfeldt, JH; Farber, MA; Franklin, S; Henriquez, M; Kopyt, N; Louis, GT; Nwachuku, C; Pressel, S; Rahman, M; Saklayen, M; Stanford, C; Walworth, C; Ward, H; Whelton, PK; Wiegmann, T; Wright, JT, 2006) |
| "Stable patients with coronary disease and > or =3 anginal attacks per week despite maximum recommended dosage of amlodipine (10 mg/day) were randomized to 1,000 mg ranolazine or placebo twice a day for 6 weeks." | 5.12 | Antianginal efficacy of ranolazine when added to treatment with amlodipine: the ERICA (Efficacy of Ranolazine in Chronic Angina) trial. ( Blokhin, A; Gratsiansky, NA; Huang, IZ; Meng, L; Stone, PH, 2006) |
| " The present study compared the chronic effects of efonidipine and amlodipine on proteinuria in patients with chronic glomerulonephritis." | 5.12 | Efonidipine reduces proteinuria and plasma aldosterone in patients with chronic glomerulonephritis. ( Akashiba, A; Ishimitsu, T; Kameda, T; Matsuoka, H; Minami, J; Numabe, A; Ohta, S; Ono, H; Takahashi, T; Yoshii, M, 2007) |
| "To determine whether, at trough levels, ranolazine improves the total exercise time of patients who have symptoms of chronic angina and who experience angina and ischemia at low workloads despite taking standard doses of atenolol, amlodipine, or diltiazem and to determine times to angina onset and to electrocardiographic evidence of myocardial ischemia, effect on angina attacks and nitroglycerin use, and effect on long-term survival in an open-label observational study extension." | 5.11 | Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial. ( Chaitman, BR; Chumakova, G; Kuch, J; Parker, JO; Pepine, CJ; Skettino, SL; Skopal, J; Wang, W; Wolff, AA, 2004) |
| " Our aim was to prospectively compare the effects of amlodipine and ACEI (enalapril) on renal function in hypertensive patients with renal impairment due to chronic glomerulonephritis and essential hypertension." | 5.09 | Amlodipine is comparable to angiotensin-converting enzyme inhibitor for long-term renoprotection in hypertensive patients with renal dysfunction: a one-year, prospective, randomized study. ( Hayashi, K; Kumagai, H; Kumamaru, H; Saruta, T, 2000) |
| "The results of this study show that once daily amlodipine offers comparable antianginal and antiischemic efficacy as twice daily sustained release nifedipine in the monotreatment of chronic stable angina pectoris." | 5.09 | [Amlodipine versus nifedipine retard. A randomized double-blind comparative study on long-term efficacy and safety of amlodipine and nifedipine retard in the monotherapy of chronic stable angina pectoris]. ( Kupper, W; Sauerbrey-Wullkopf, N, 2001) |
| "The efficacy and safety of amlodipine, 10 mg, a new long-acting calcium antagonist, was compared with placebo in 103 patients with stable angina pectoris in a multicenter double-blind crossover study." | 5.08 | Amlodipine in chronic stable angina: results of a multicenter double-blind crossover trial. ( Awan, N; Bommer, W; Ezekowitz, MD; Grossman, W; Hossack, K; Kostuk, W; Mehta, JL; Thadani, U; Weidler, DJ, 1995) |
| "The safety and tolerability of mibefradil, a selective T-type calcium channel antagonist, were evaluated in 3,430 patients with essential hypertension and chronic stable angina pectoris treated in 15 double-blind placebo and active-controlled clinical trials and 2 open-label, long-term safety studies." | 5.08 | Safety of mibefradil, a new once-a-day, selective T-type calcium channel antagonist. ( Charlon, V; Kobrin, I; Lindberg, E; Pordy, R, 1997) |
| "To assess the effect of short-term amlodipine therapy on baseline measures of sympathetic activity and baroreflex function in patients with chronic stable congestive heart failure (CHF)." | 5.08 | Effect of amlodipine on norepinephrine kinetics and baroreflex function in patients with congestive heart failure. ( Goldsmith, SR, 1997) |
| "Amlodipine did not increase cardiovascular morbidity or mortality in patients with severe heart failure." | 5.08 | Effect of amlodipine on morbidity and mortality in severe chronic heart failure. Prospective Randomized Amlodipine Survival Evaluation Study Group. ( Belkin, RN; Carson, PE; Cropp, AB; DeMets, DL; Frid, D; Ghali, JK; Miller, AB; Neuberg, GW; O'Connor, CM; Packer, M; Pressler, ML; Wertheimer, JH, 1996) |
| "This study evaluated the safety, antianginal and antiischemic effects of amlodipine, a dihydropyridine calcium antagonist, in patients with chronic stable angina pectoris." | 5.06 | Clinical safety and efficacy of once-a-day amlodipine for chronic stable angina pectoris. ( Glasser, SP; West, TW, 1988) |
| " The incidence of severe hypertension was significantly lower when nifedipine (odds ratio, 0." | 5.05 | Comparative efficacy and safety of oral antihypertensive agents in pregnant women with chronic hypertension: a network metaanalysis. ( Bellos, I; Daskalakis, G; Loutradis, D; Papapanagiotou, A; Pergialiotis, V, 2020) |
| "Patients ≥65years-old with a diagnosis of hypertension and/or dyslipidaemia receiving treatment with Enalapril and/or Amlodipine and/or Simvastatin." | 3.96 | [Effects of changing the appearance of medications in safety and adherence in chronic patients over 65 years of age in primary care. CAMBIMED Study]. ( Arancón-Monge, JM; Campos-Díaz, L; de Castro-Cuenca, A; Del Cura-González, I; Rodríguez Barrientos, R; Serrano-Vázquez, Á, 2020) |
| "Background Amlodipine is used for the treatment of hypertension, but reports on its use in early pregnancy are limited." | 3.91 | Safety of Amlodipine in Early Pregnancy. ( Arata, N; Ito, S; Kamiya, CA; Mikami, M; Mito, A; Miyasato-Isoda, M; Murashima, A; Suzuki, T; Wada, Y; Waguri, M; Watanabe, O; Yakuwa, N; Yoshimatsu, J, 2019) |
| "Amlodipine is rarely used in the treatment of pregnant hypertensive women due to limited pharmacokinetic data during pregnancy and the postpartum period." | 3.88 | Pharmacokinetics of amlodipine besylate at delivery and during lactation. ( Kogutt, BK; McIntire, DD; Meek, C; Morgan, JL; Roberts, SW; Sheffield, JS; Stehel, EK, 2018) |
| "Treatment with candesartan cilexetil reduced the level of ADMA in hypertensive patients in the chronic stage of cerebral infarction." | 3.83 | Effects of Candesartan Cilexetil Compared with Amlodipine on Serum Asymmetric Dimethylarginine Levels in the Chronic Stage of Cerebral Infarction: A Preliminary Study. ( Katayama, Y; Nishiyama, Y; Nomura, K; Sunami, E, 2016) |
| "To report a case of conjunctival chemosis and bipedal edema associated with amlodipine besylate antihypertensive medication." | 3.77 | Chronic conjunctival chemosis from amlodipine besylate (Norvasc). ( Bianciotto, C; Say, EA; Shields, CL; Shields, JA, 2011) |
| "Our data show that the effects of losartan and amlodipine on the absolute mean reduction of blood pressure and proteinuria in non-diabetic nephropathy patients are similar between the different ACE or AGT genotypes." | 3.73 | [Pharmacogenetics of angiotensin system in non diabetic nephropathy]. ( Alvarez, V; Arias, M; Campistol, JM; Coto, E; Fernández Andrade, C; Galcerán, JM; Luño, J; Marín, R; Poveda, R; Praga, M; Rivera, F; Vallés, M, 2005) |
| " Male Wistar rats with ligation-induced myocardial infarction were assigned to placebo or treatment with mibefradil (10 mg/kg/day), verapamil (8 mg/kg/day), or amlodipine (4 mg/kg/day) by oral gavage starting 7 days before the induction of myocardial infarction." | 3.70 | Differential effects of mibefradil, verapamil, and amlodipine on myocardial function and intracellular Ca(2+) handling in rats with chronic myocardial infarction. ( Meissner, A; Min, JY; Sandmann, S; Simon, R; Unger, T, 1999) |
| "The authors report the results of therapy with amlodipine in 20 patients with mild or moderate hypertension (diastolic pressure between 95 and 115 mmHg)." | 3.68 | [Experience with amlodipine (Norvasc) in the management of arterial hypertension]. ( Domínguez, B; Rodríguez, N, 1993) |
| "Proteinuria was positively correlated with circulating AGE and sRAGE levels in our subjects." | 2.76 | Calcium channel blocker inhibition of AGE and RAGE axis limits renal injury in nondiabetic patients with stage I or II chronic kidney disease. ( Fujiwara, N; Kawagoe, Y; Koide, H; Nakamura, T; Sato, E; Takeuchi, M; Ueda, Y; Yamagishi, S, 2011) |
| "Atorvastatin was as potent an anti-ischaemic agent as amlodipine." | 2.75 | Potent anti-ischaemic effects of statins in chronic stable angina: incremental benefit beyond lipid lowering? ( Beckerman, B; Buch, J; Bultas, J; Deanfield, JE; Sellier, P; Shi, H; Thaulow, E; Yunis, C, 2010) |
| "This multicenter, randomized, double-blind, parallel group, placebo lead-in, placebo-controlled study compared the antianginal and anti-ischemic effects of once-daily bedtime dosing of controlled-onset extended-release (COER-24) verapamil to a once-daily morning dosing of amlodipine +/- atenolol in patients with chronic stable angina." | 2.69 | Comparison of controlled-onset, extended-release verapamil with amlodipine and amlodipine plus atenolol on exercise performance and ambulatory ischemia in patients with chronic stable angina pectoris. ( Deedwania, PC; Fakouhi, TD; Frishman, WH; Glasser, S; Johnson, M; Stone, P, 1999) |
| "Mibefradil-treated patients showed greater decreases in heart rate and the rate-pressure product at each stage of the ETT than patients treated with amlodipine or diltiazem SR." | 2.68 | Mibefradil in the treatment of chronic stable angina pectoris: comparative studies with other calcium antagonists. ( Davies, GJ; Kobrin, I; Tzivoni, D, 1997) |
| "The efficacy of amlodipine, a long half-life dihydropyridine calcium antagonist, at the dosage of 5-10 mg/day in a single daily administration, has been compared with that of nifedipine R, a short half-life dihydropyridine, at the dosage of 20-40 mg b." | 2.67 | Amlodipine versus nifedipine retard in the treatment of chronic ischemic heart disease. ( Cardillo, R; Castelli, D; Circo, A; Mangiameli, S; Platania, F; Scaccianoce, G, 1992) |
| "Mibefradil is a recently developed calcium antagonist with a unique chemical structure, pharmacologic profile, and mode of action." | 2.40 | Mibefradil, a T-type channel-selective calcium antagonist: clinical trials in chronic stable angina pectoris. ( Massie, BM, 1998) |
| "Hypertension is a chronic condition that requires lifelong therapeutic management." | 1.62 | Long-acting tunable release of amlodipine loaded PEG-PCL micelles for tailored treatment of chronic hypertension. ( Chua, CYX; Di Trani, N; Grattoni, A; Liu, HC; Liu, X; Qi, R; Viswanath, DI, 2021) |
| "Hypertension is present in nearly 80% of dialysis patients yet adequately controlled in less than half." | 1.34 | ACE inhibitor-based, directly observed therapy for hypertension in hemodialysis patients. ( Coyne, DW; Nath, V; Zheng, S, 2007) |
| " In 11 patients concomitantly treated with cyclosporine the dosage and the trough-level of this agent were stable throughout the trial." | 1.31 | Antihypertensive efficacy of amlodipine in children with chronic kidney diseases. ( Bianchetti, MG; Bianda, ND; Casaulta Aebischer, C; Franscini, LM; Pfister, R; von Vigier, RO, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (5.17) | 18.7374 |
| 1990's | 16 (27.59) | 18.2507 |
| 2000's | 21 (36.21) | 29.6817 |
| 2010's | 15 (25.86) | 24.3611 |
| 2020's | 3 (5.17) | 2.80 |
| Authors | Studies |
|---|---|
| Arancón-Monge, JM | 1 |
| de Castro-Cuenca, A | 1 |
| Serrano-Vázquez, Á | 1 |
| Campos-Díaz, L | 1 |
| Rodríguez Barrientos, R | 1 |
| Del Cura-González, I | 1 |
| Bellos, I | 1 |
| Pergialiotis, V | 1 |
| Papapanagiotou, A | 1 |
| Loutradis, D | 1 |
| Daskalakis, G | 1 |
| Di Trani, N | 1 |
| Liu, HC | 1 |
| Qi, R | 1 |
| Viswanath, DI | 1 |
| Liu, X | 1 |
| Chua, CYX | 1 |
| Grattoni, A | 1 |
| Kar, SK | 1 |
| Srivastava, A | 1 |
| Yoo, J | 1 |
| Jue, MS | 1 |
| Morgan, JL | 1 |
| Kogutt, BK | 1 |
| Meek, C | 1 |
| Stehel, EK | 1 |
| McIntire, DD | 1 |
| Sheffield, JS | 1 |
| Roberts, SW | 1 |
| Mito, A | 1 |
| Murashima, A | 1 |
| Wada, Y | 1 |
| Miyasato-Isoda, M | 1 |
| Kamiya, CA | 1 |
| Waguri, M | 1 |
| Yoshimatsu, J | 1 |
| Yakuwa, N | 1 |
| Watanabe, O | 1 |
| Suzuki, T | 2 |
| Arata, N | 1 |
| Mikami, M | 1 |
| Ito, S | 1 |
| Packer, M | 3 |
| Carson, P | 1 |
| Elkayam, U | 1 |
| Konstam, MA | 1 |
| Moe, G | 1 |
| O'Connor, C | 1 |
| Rouleau, JL | 1 |
| Schocken, D | 1 |
| Anderson, SA | 1 |
| DeMets, DL | 2 |
| Kim, KH | 1 |
| Kim, WS | 1 |
| Sunami, E | 1 |
| Nomura, K | 1 |
| Nishiyama, Y | 1 |
| Katayama, Y | 1 |
| Tepel, M | 1 |
| Hopfenmueller, W | 1 |
| Scholze, A | 1 |
| Maier, A | 1 |
| Zidek, W | 1 |
| Nakamura, T | 2 |
| Inoue, T | 1 |
| Kawagoe, Y | 2 |
| Ueda, Y | 2 |
| Koide, H | 2 |
| Node, K | 1 |
| Kamalov, G | 1 |
| Deshmukh, PA | 1 |
| Baburyan, NY | 1 |
| Gandhi, MS | 1 |
| Johnson, PL | 1 |
| Ahokas, RA | 1 |
| Bhattacharya, SK | 1 |
| Sun, Y | 1 |
| Gerling, IC | 1 |
| Weber, KT | 1 |
| Saruta, T | 3 |
| Hayashi, K | 3 |
| Ogihara, T | 1 |
| Nakao, K | 1 |
| Fukui, T | 1 |
| Fukiyama, K | 1 |
| Takahara, A | 1 |
| Nakamura, Y | 1 |
| Wagatsuma, H | 1 |
| Aritomi, S | 1 |
| Nakayama, A | 1 |
| Satoh, Y | 1 |
| Akie, Y | 1 |
| Sugiyama, A | 1 |
| Izzo, JL | 1 |
| Purkayastha, D | 1 |
| Hall, D | 1 |
| Hilkert, RJ | 1 |
| Deanfield, JE | 1 |
| Sellier, P | 1 |
| Thaulow, E | 2 |
| Bultas, J | 1 |
| Yunis, C | 1 |
| Shi, H | 1 |
| Buch, J | 1 |
| Beckerman, B | 1 |
| Slagman, MC | 1 |
| Navis, G | 1 |
| Laverman, GD | 1 |
| Say, EA | 1 |
| Shields, CL | 1 |
| Bianciotto, C | 1 |
| Shields, JA | 1 |
| Abe, M | 1 |
| Okada, K | 1 |
| Maruyama, N | 1 |
| Matsumoto, S | 1 |
| Maruyama, T | 1 |
| Fujita, T | 1 |
| Matsumoto, K | 1 |
| Soma, M | 1 |
| Sato, E | 1 |
| Fujiwara, N | 1 |
| Takeuchi, M | 1 |
| Yamagishi, S | 1 |
| Takenaka, T | 1 |
| Uchida, K | 1 |
| Kojima, E | 1 |
| Gen, S | 1 |
| Nodaira, Y | 1 |
| Hoshi, H | 1 |
| Kato, N | 1 |
| Takane, H | 1 |
| Ohno, Y | 1 |
| Suzuki, H | 1 |
| Rahman, M | 2 |
| Ford, CE | 1 |
| Cutler, JA | 1 |
| Davis, BR | 2 |
| Piller, LB | 1 |
| Whelton, PK | 2 |
| Wright, JT | 2 |
| Barzilay, JI | 1 |
| Brown, CD | 1 |
| Colon, PJ | 1 |
| Fine, LJ | 1 |
| Grimm, RH | 1 |
| Gupta, AK | 1 |
| Baimbridge, C | 1 |
| Haywood, LJ | 1 |
| Henriquez, MA | 1 |
| Ilamaythi, E | 1 |
| Oparil, S | 1 |
| Preston, R | 1 |
| Obiechina, NS | 1 |
| Fine, JB | 1 |
| Chaitman, BR | 1 |
| Pepine, CJ | 1 |
| Parker, JO | 1 |
| Skopal, J | 1 |
| Chumakova, G | 1 |
| Kuch, J | 1 |
| Wang, W | 1 |
| Skettino, SL | 1 |
| Wolff, AA | 1 |
| Homma, K | 1 |
| Kanda, T | 1 |
| Yoshioka, K | 1 |
| Takamatsu, I | 1 |
| Tatematsu, S | 1 |
| Kumagai, H | 2 |
| Wakino, S | 1 |
| Gratsianskiĭ, NA | 1 |
| Coto, E | 1 |
| Marín, R | 1 |
| Alvarez, V | 1 |
| Praga, M | 1 |
| Fernández Andrade, C | 1 |
| Arias, M | 1 |
| Poveda, R | 1 |
| Vallés, M | 1 |
| Galcerán, JM | 1 |
| Luño, J | 1 |
| Rivera, F | 1 |
| Campistol, JM | 1 |
| Pressel, S | 1 |
| Nwachuku, C | 1 |
| Barzilay, J | 1 |
| Batuman, V | 1 |
| Eckfeldt, JH | 1 |
| Farber, MA | 1 |
| Franklin, S | 1 |
| Henriquez, M | 1 |
| Kopyt, N | 1 |
| Louis, GT | 1 |
| Saklayen, M | 1 |
| Stanford, C | 1 |
| Walworth, C | 1 |
| Ward, H | 1 |
| Wiegmann, T | 1 |
| Stone, PH | 1 |
| Gratsiansky, NA | 1 |
| Blokhin, A | 1 |
| Huang, IZ | 1 |
| Meng, L | 1 |
| Zheng, S | 1 |
| Nath, V | 1 |
| Coyne, DW | 1 |
| Ishimitsu, T | 1 |
| Kameda, T | 1 |
| Akashiba, A | 1 |
| Takahashi, T | 1 |
| Ohta, S | 1 |
| Yoshii, M | 1 |
| Minami, J | 1 |
| Ono, H | 1 |
| Numabe, A | 1 |
| Matsuoka, H | 1 |
| Tereshenko, SN | 1 |
| Zhirov, IV | 1 |
| Uspenskaia, OV | 1 |
| Ezekowitz, MD | 1 |
| Hossack, K | 1 |
| Mehta, JL | 1 |
| Thadani, U | 1 |
| Weidler, DJ | 1 |
| Kostuk, W | 1 |
| Awan, N | 1 |
| Grossman, W | 1 |
| Bommer, W | 1 |
| Patel, VB | 1 |
| Siddiq, T | 1 |
| Richardson, PJ | 1 |
| Marway, JS | 1 |
| Paice, AG | 1 |
| Preedy, VR | 1 |
| Rodríguez, N | 1 |
| Domínguez, B | 1 |
| Woodmansey, PA | 1 |
| Zhang, F | 1 |
| Channer, KS | 1 |
| Morice, AH | 1 |
| del Río Fernández, MC | 1 |
| Plagaro Cordero, ME | 1 |
| de Frutos Arribas, JF | 1 |
| del Pozo Román, T | 1 |
| Martín Escudero, JC | 1 |
| O'Connor, CM | 2 |
| Ghali, JK | 1 |
| Pressler, ML | 2 |
| Carson, PE | 2 |
| Belkin, RN | 2 |
| Miller, AB | 2 |
| Neuberg, GW | 2 |
| Frid, D | 1 |
| Wertheimer, JH | 2 |
| Cropp, AB | 2 |
| Poole-Wilson, PA | 1 |
| Goldsmith, SR | 1 |
| Davies, GJ | 1 |
| Tzivoni, D | 1 |
| Kobrin, I | 2 |
| Charlon, V | 1 |
| Lindberg, E | 1 |
| Pordy, R | 1 |
| Walsh, JT | 1 |
| Andrews, R | 1 |
| Curtis, S | 1 |
| Evans, A | 1 |
| Cowley, AJ | 1 |
| Massie, BM | 1 |
| Frishman, WH | 1 |
| Glasser, S | 1 |
| Stone, P | 1 |
| Deedwania, PC | 1 |
| Johnson, M | 1 |
| Fakouhi, TD | 1 |
| Klinge, R | 1 |
| Jørgensen, B | 1 |
| Sirnes, PA | 1 |
| Hall, C | 1 |
| Min, JY | 1 |
| Sandmann, S | 1 |
| Meissner, A | 1 |
| Unger, T | 1 |
| Simon, R | 1 |
| Kumamaru, H | 1 |
| Sauerbrey-Wullkopf, N | 1 |
| Kupper, W | 1 |
| von Vigier, RO | 1 |
| Franscini, LM | 1 |
| Bianda, ND | 1 |
| Pfister, R | 1 |
| Casaulta Aebischer, C | 1 |
| Bianchetti, MG | 1 |
| Baylis, C | 1 |
| Qiu, C | 1 |
| Engels, K | 1 |
| Frid, DJ | 1 |
| Nye, RG | 1 |
| Circo, A | 1 |
| Scaccianoce, G | 1 |
| Platania, F | 1 |
| Castelli, D | 1 |
| Cardillo, R | 1 |
| Mangiameli, S | 1 |
| Glasser, SP | 2 |
| West, TW | 2 |
| Deedwania, P | 1 |
| Cheitlin, M | 1 |
| Das, S | 1 |
| Pool, P | 1 |
| Singh, J | 1 |
| Pasternak, R | 1 |
| Carabello, B | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Influence of Amlodipine on the Mortality of Patients With End-Stage Renal Failure (ADAM [Amlodipine and Dialysis Patients, Action on Mortality])[NCT00124969] | Phase 4 | 356 participants (Actual) | Interventional | 2002-01-31 | Completed | ||
| A 6-Week Multi-center, Randomized, Double-Blind, Parallel Group Study Comparing the Efficacy of Amlodipine Besylate/Benazepril Versus Amlodipine in the Treatment of Severe Hypertension[NCT00136851] | Phase 4 | 259 participants (Actual) | Interventional | 2004-12-31 | Completed | ||
| Double Blind Atorvastatin Amlodipine Study (DUAAL) Effect Of Amlodipine, Atorvastatin And The Combination On Transient Myocardia Ischemia In Coronary Artery Disease.[NCT00159718] | Phase 4 | 360 participants | Interventional | 2001-07-31 | Completed | ||
| [NCT00000542] | Phase 3 | 0 participants | Interventional | 1993-08-31 | Completed | ||
| A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study of Ranolazine SR at a Dose of 1000 mg Twice a Day in Patients With Chronic Angina Who Remain Symptomatic Despite Treatment With Amlodipine 10 mg Once a Day[NCT00091429] | Phase 3 | 500 participants | Interventional | 2004-08-31 | Completed | ||
| Effect of Ranolazine on Activity Level in Patients With Angina After FFR Based Deferred Intervention[NCT03044964] | Phase 4 | 40 participants (Anticipated) | Interventional | 2017-01-10 | Recruiting | ||
| Regional and Systemic Hemodynamic Effects of a Long-term Administration of Amlodipine in Patients With Chronic Heart Failure Treated With a Combination of Enalapril, Furosemide and Digoxin[NCT00151619] | Phase 2 | 7 participants (Actual) | Interventional | 1999-02-10 | Terminated | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for amlodipine and Chronic Illness
| Article | Year |
|---|---|
Comparative efficacy and safety of oral antihypertensive agents in pregnant women with chronic hypertension: a network metaanalysis.
Topics: Abruptio Placentae; Amlodipine; Antihypertensive Agents; Atenolol; Cesarean Section; Chronic Disease | 2020 |
Mibefradil, a T-type channel-selective calcium antagonist: clinical trials in chronic stable angina pectoris.
Topics: Amlodipine; Angina Pectoris; Benzimidazoles; Calcium Channel Blockers; Chronic Disease; Clinical Tri | 1998 |
30 trials available for amlodipine and Chronic Illness
| Article | Year |
|---|---|
Effect of amlodipine on the survival of patients with severe chronic heart failure due to a nonischemic cardiomyopathy: results of the PRAISE-2 study (prospective randomized amlodipine survival evaluation 2).
Topics: Amlodipine; Calcium Channel Blockers; Cardiomyopathies; Chronic Disease; Double-Blind Method; Female | 2013 |
Effect of amlodipine on cardiovascular events in hypertensive haemodialysis patients.
Topics: Aged; Amlodipine; Blood Pressure; Calcium Channel Blockers; Cardiovascular Diseases; Chronic Disease | 2008 |
Comparison of renal and vascular protective effects between telmisartan and amlodipine in hypertensive patients with chronic kidney disease with mild renal insufficiency.
Topics: Adult; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Blood Pressu | 2008 |
Effects of candesartan and amlodipine on cardiovascular events in hypertensive patients with chronic kidney disease: subanalysis of the CASE-J Study.
Topics: Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Blood | 2009 |
Comparative efficacy and safety of amlodipine/benazepril combination therapy and amlodipine monotherapy in severe hypertension.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amlodipine; Antihypertensive Agents; Benzazepines; Chron | 2010 |
Potent anti-ischaemic effects of statins in chronic stable angina: incremental benefit beyond lipid lowering?
Topics: Aged, 80 and over; Amlodipine; Angina, Stable; Antihypertensive Agents; Atorvastatin; Chronic Diseas | 2010 |
Benidipine reduces albuminuria and plasma aldosterone in mild-to-moderate stage chronic kidney disease with albuminuria.
Topics: Aged; Albuminuria; Aldosterone; Amlodipine; Angiotensin Receptor Antagonists; Blood Pressure; Calciu | 2011 |
Calcium channel blocker inhibition of AGE and RAGE axis limits renal injury in nondiabetic patients with stage I or II chronic kidney disease.
Topics: Adult; Amlodipine; Analysis of Variance; Angiotensin II Type 1 Receptor Blockers; Antihypertensive A | 2011 |
Long-term renal and cardiovascular outcomes in Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) participants by baseline estimated GFR.
Topics: Amlodipine; Antihypertensive Agents; Canada; Chlorthalidone; Chronic Disease; Coronary Disease; Doub | 2012 |
Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial.
Topics: Acetanilides; Adrenergic beta-Antagonists; Aged; Amlodipine; Angina Pectoris; Atenolol; Calcium Chan | 2004 |
Beneficial action of candesartan cilexetil plus amlodipine or ACE inhibitors in chronic nondiabetic renal disease.
Topics: Adult; Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhi | 2004 |
Cardiovascular outcomes in high-risk hypertensive patients stratified by baseline glomerular filtration rate.
Topics: Aged; Amlodipine; Antihypertensive Agents; Cardiovascular Diseases; Chlorthalidone; Chronic Disease; | 2006 |
Antianginal efficacy of ranolazine when added to treatment with amlodipine: the ERICA (Efficacy of Ranolazine in Chronic Angina) trial.
Topics: Acetanilides; Aged; Amlodipine; Angina Pectoris; Chronic Disease; Coronary Disease; Double-Blind Met | 2006 |
Antianginal efficacy of ranolazine when added to treatment with amlodipine: the ERICA (Efficacy of Ranolazine in Chronic Angina) trial.
Topics: Acetanilides; Aged; Amlodipine; Angina Pectoris; Chronic Disease; Coronary Disease; Double-Blind Met | 2006 |
Antianginal efficacy of ranolazine when added to treatment with amlodipine: the ERICA (Efficacy of Ranolazine in Chronic Angina) trial.
Topics: Acetanilides; Aged; Amlodipine; Angina Pectoris; Chronic Disease; Coronary Disease; Double-Blind Met | 2006 |
Antianginal efficacy of ranolazine when added to treatment with amlodipine: the ERICA (Efficacy of Ranolazine in Chronic Angina) trial.
Topics: Acetanilides; Aged; Amlodipine; Angina Pectoris; Chronic Disease; Coronary Disease; Double-Blind Met | 2006 |
Efonidipine reduces proteinuria and plasma aldosterone in patients with chronic glomerulonephritis.
Topics: Adult; Aged; Aldosterone; Amlodipine; Blood Pressure; Calcium Channel Blockers; Calcium Channels, L- | 2007 |
[The role of amlodipine in the treatment of chronic heart failure in women].
Topics: Aged; Amlodipine; Antihypertensive Agents; Calcium Channel Blockers; Chronic Disease; Drug Administr | 2007 |
Amlodipine in chronic stable angina: results of a multicenter double-blind crossover trial.
Topics: Adult; Aged; Amlodipine; Angina Pectoris; Chronic Disease; Cross-Over Studies; Double-Blind Method; | 1995 |
Effect of amlodipine on morbidity and mortality in severe chronic heart failure. Prospective Randomized Amlodipine Survival Evaluation Study Group.
Topics: Aged; Amlodipine; Calcium Channel Blockers; Cardiomyopathy, Dilated; Chronic Disease; Double-Blind M | 1996 |
Effect of amlodipine on norepinephrine kinetics and baroreflex function in patients with congestive heart failure.
Topics: Aged; Amlodipine; Baroreflex; Blood Pressure; Calcium Channel Blockers; Cardiotonic Agents; Chronic | 1997 |
Mibefradil in the treatment of chronic stable angina pectoris: comparative studies with other calcium antagonists.
Topics: Adult; Aged; Aged, 80 and over; Amlodipine; Angina Pectoris; Benzimidazoles; Calcium Channel Blocker | 1997 |
Safety of mibefradil, a new once-a-day, selective T-type calcium channel antagonist.
Topics: Aged; Amlodipine; Angina Pectoris; Benzimidazoles; Calcium Channel Blockers; Chronic Disease; Drug A | 1997 |
Effects of amlodipine in patients with chronic heart failure.
Topics: Aged; Amlodipine; Calcium Channel Blockers; Chronic Disease; Double-Blind Method; Exercise Test; Exe | 1997 |
Comparison of controlled-onset, extended-release verapamil with amlodipine and amlodipine plus atenolol on exercise performance and ambulatory ischemia in patients with chronic stable angina pectoris.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Amlodipine; Angina Pectoris; Atenolol; Calcium | 1999 |
N-terminal proatrial natriuretic peptide in angina pectoris: impact of revascularization by angioplasty.
Topics: Adult; Age Factors; Aged; Amlodipine; Angina Pectoris; Angioplasty, Balloon, Coronary; Atrial Natriu | 1999 |
Amlodipine is comparable to angiotensin-converting enzyme inhibitor for long-term renoprotection in hypertensive patients with renal dysfunction: a one-year, prospective, randomized study.
Topics: Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Calcium Channel Blockers; Captopril; Chr | 2000 |
[Amlodipine versus nifedipine retard. A randomized double-blind comparative study on long-term efficacy and safety of amlodipine and nifedipine retard in the monotherapy of chronic stable angina pectoris].
Topics: Adult; Aged; Amlodipine; Angina Pectoris; Calcium Channel Blockers; Chronic Disease; Data Interpreta | 2001 |
Diuretic resistance predicts mortality in patients with advanced heart failure.
Topics: Aged; Amlodipine; Analysis of Variance; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; D | 2002 |
Amlodipine versus nifedipine retard in the treatment of chronic ischemic heart disease.
Topics: Adult; Aged; Amlodipine; Calcium Channel Blockers; Chronic Disease; Coronary Disease; Delayed-Action | 1992 |
Clinical safety and efficacy of once-daily amlodipine for chronic stable angina pectoris.
Topics: Amlodipine; Angina Pectoris; Calcium Channel Blockers; Chronic Disease; Drug Administration Schedule | 1989 |
Double-blind crossover comparison of amlodipine at three dose levels and placebo in chronic stable angina.
Topics: Aged; Amlodipine; Angina Pectoris; Chronic Disease; Double-Blind Method; Exercise Test; Female; Huma | 1989 |
Clinical safety and efficacy of once-a-day amlodipine for chronic stable angina pectoris.
Topics: Aged; Amlodipine; Angina Pectoris; Blood Pressure; Chronic Disease; Clinical Trials as Topic; Double | 1988 |
26 other studies available for amlodipine and Chronic Illness
| Article | Year |
|---|---|
[Effects of changing the appearance of medications in safety and adherence in chronic patients over 65 years of age in primary care. CAMBIMED Study].
Topics: Aged; Aged, 80 and over; Amlodipine; Antihypertensive Agents; Chronic Disease; Drug Labeling; Drug P | 2020 |
Long-acting tunable release of amlodipine loaded PEG-PCL micelles for tailored treatment of chronic hypertension.
Topics: Amlodipine; Animals; Calcium Channel Blockers; Calcium Channels; Cell Line; Cell Survival; Chronic D | 2021 |
Attributions to new onset catatonic symptoms, late in the course of chronic schizophrenia.
Topics: Amlodipine; Antihypertensive Agents; Antipsychotic Agents; Aripiprazole; Catatonia; Chronic Disease; | 2017 |
Intractable pruritus with chronic eczema in an elderly patient caused by long-term intake of calcium channel blocker.
Topics: Aged; Amlodipine; Calcium Channel Blockers; Chronic Disease; Drug Eruptions; Eczema; Humans; Male; P | 2017 |
Pharmacokinetics of amlodipine besylate at delivery and during lactation.
Topics: Adult; Amlodipine; Antihypertensive Agents; Chronic Disease; Delivery, Obstetric; Drug Monitoring; F | 2018 |
Safety of Amlodipine in Early Pregnancy.
Topics: Abnormalities, Drug-Induced; Aged; Amlodipine; Antihypertensive Agents; Chronic Disease; Female; Fol | 2019 |
Chronic unilateral chemosis following the use of amlodipine besylate.
Topics: Amlodipine; Calcium Channel Blockers; Chronic Disease; Conjunctival Diseases; Drug Substitution; Hum | 2014 |
Effects of Candesartan Cilexetil Compared with Amlodipine on Serum Asymmetric Dimethylarginine Levels in the Chronic Stage of Cerebral Infarction: A Preliminary Study.
Topics: Aged; Aged, 80 and over; Amlodipine; Antihypertensive Agents; Arginine; Benzimidazoles; Biomarkers; | 2016 |
Coupled calcium and zinc dyshomeostasis and oxidative stress in cardiac myocytes and mitochondria of rats with chronic aldosteronism.
Topics: Aldehydes; Aldosterone; Amlodipine; Animals; Calcium; Calcium Channel Blockers; Chronic Disease; Dis | 2009 |
Long-term blockade of L/N-type Ca(2+) channels by cilnidipine ameliorates repolarization abnormality of the canine hypertrophied heart.
Topics: Action Potentials; Amlodipine; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Atr | 2009 |
Reversible effects of diuretics added to renin-angiotensin-aldosterone system blockade: impact on interpretation of long-term kidney function outcome.
Topics: Amlodipine; Chronic Disease; Data Interpretation, Statistical; Diuretics; Humans; Hydrochlorothiazid | 2010 |
Chronic conjunctival chemosis from amlodipine besylate (Norvasc).
Topics: Aged; Amlodipine; Antihypertensive Agents; Chronic Disease; Conjunctival Diseases; Edema; Foot Disea | 2011 |
Amlodipine and loop diuretics as the second anti-hypertensive medication for the treatment of hypertension with chronic kidney diseases.
Topics: Aged; Amlodipine; Angiotensin II Type 2 Receptor Blockers; Antihypertensive Agents; Blood Pressure; | 2011 |
Case report: treatment of amlodipine associated gingival overgrowth in periodontitis patients.
Topics: Alveolar Bone Loss; Amlodipine; Antihypertensive Agents; Chronic Disease; Dental Calculus; Dental Sc | 2000 |
[Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina. Results of CARISA].
Topics: Acetanilides; Adrenergic beta-Antagonists; Amlodipine; Angina Pectoris; Atenolol; Cardiovascular Age | 2004 |
[Pharmacogenetics of angiotensin system in non diabetic nephropathy].
Topics: Adult; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Calcium Channel | 2005 |
Summaries for patients. Do the effects of blood pressure drugs differ by kidney function?
Topics: Aged; Amlodipine; Antihypertensive Agents; Cardiovascular Diseases; Chlorthalidone; Chronic Disease; | 2006 |
ACE inhibitor-based, directly observed therapy for hypertension in hemodialysis patients.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Anti | 2007 |
The regression of chronic hypertrophy by a calcium channel antagonist and an ACE-inhibitor.
Topics: Amlodipine; Animals; Blood Pressure; Cardiomegaly; Chronic Disease; Lisinopril; Male; Muscle Protein | 1994 |
[Experience with amlodipine (Norvasc) in the management of arterial hypertension].
Topics: Adult; Aged; Amlodipine; Blood Pressure; Chronic Disease; Drug Evaluation; Female; Humans; Hypertens | 1993 |
Vasodilatory action of the calcium antagonist amlodipine on large and resistance pulmonary arteries from normoxic and chronically hypoxic rats.
Topics: Amlodipine; Animals; Aorta; Chronic Disease; Dose-Response Relationship, Drug; Hypertension, Pulmona | 1993 |
[Leukocytoclastic vasculitis in relation to amlodipine administration].
Topics: Adult; Amlodipine; Antihypertensive Agents; Calcium Channel Blockers; Chronic Disease; Humans; Hyper | 1995 |
Amlodipine in chronic heart failure.
Topics: Amlodipine; Calcium Channel Blockers; Cardiomyopathy, Dilated; Chronic Disease; Coronary Angiography | 1997 |
Differential effects of mibefradil, verapamil, and amlodipine on myocardial function and intracellular Ca(2+) handling in rats with chronic myocardial infarction.
Topics: Adrenergic beta-Agonists; Aequorin; Amlodipine; Animals; Calcium; Calcium Channel Blockers; Chronic | 1999 |
Antihypertensive efficacy of amlodipine in children with chronic kidney diseases.
Topics: Adolescent; Adult; Age Factors; Amlodipine; Antihypertensive Agents; Blood Pressure; Child; Child We | 2001 |
Comparison of L-type and mixed L- and T-type calcium channel blockers on kidney injury caused by deoxycorticosterone-salt hypertension in rats.
Topics: Amlodipine; Animals; Calcium Channel Blockers; Calcium Channels, L-Type; Calcium Channels, T-Type; C | 2001 |